Skip to main content
    M

    Moderna Inc (MRNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $215.27
    -8.10 (-3.63%)

    Market Cap: $90.38B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Moderna Inc (MRNA) Earnings: Report Dates and Results

    Updated Nov 6, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Moderna (MRNA) is expected to report earnings on Feb 11, 2027. In the quarter ended Sep 30, 2026, Moderna reported EPS of $0.38, above the -$1.10 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    66%(21/32)
    Avg Surprise
    -6.73%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 11, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$2.39
    Range-$4.20 - -$1.78
    20 analysts
    Revenue Consensus
    $556.23M
    Range$458.64M - $674.23M
    18 analysts
    Reports Apr 29, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.65
    Range-$2.19 - -$0.93
    6 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.85+11.3%
    60d ago-$1.85+11.0%
    30d ago-$1.85+11.0%
    7d ago-$1.85+11.2%
    Current-$1.65
    Revenue Consensus
    $281.41M
    Range$77.00M - $462.00M
    5 analysts

    Next Report

    MRNA has an expected report date of Feb 11, 2027.

    MRNA Earnings Call

    The latest MRNA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 32 quarters below that had an estimate, MRNA beat 21, missed 10 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.31B, up 28.4% from $1.02B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.38-$1.10-$3.28 - -$0.80+134.55%BeatN/A165 up, 3 downNov 6, 2026$1.31B
    Jun 30, 2026-$1.97-$1.97-$2.35 - -$1.800.00%In lineN/A15N/AJul 31, 2026$145.00M
    Mar 31, 2026-$3.40-$2.11-$4.65 - -$1.86-61.14%MissN/A121 up, 2 downMay 1, 2026$389.00M
    Dec 31, 2025-$2.11-$2.64-$3.23 - -$2.10+20.08%BeatN/A132 up, 2 downFeb 13, 2026$678.00M
    Sep 30, 2025-$0.51-$2.16-$3.10 - -$1.31+76.39%Beat-1800.0%142 up, 2 downNov 6, 2025$1.02B
    Jun 30, 2025-$2.13-$3.00-$3.58 - -$2.63+29.00%BeatN/A120 up, 2 downAug 1, 2025$142.00M
    Mar 31, 2025-$2.52-$3.11-$3.60 - -$2.91+18.97%BeatN/A121 up, 2 downMay 1, 2025$108.00M
    Dec 31, 2024-$2.91-$2.76-$3.37 - -$1.05-5.44%Miss-629.1%142 up, 4 downFeb 14, 2025$966.00M
    Sep 30, 2024$0.03-$1.90-$2.58 - -$1.33+101.58%BeatN/A163 up, 0 downNov 7, 2024$1.86B
    Jun 30, 2024-$3.33-$3.35-$4.20 - -$2.93+0.60%BeatN/A160 up, 1 downAug 1, 2024$241.00M
    Mar 31, 2024-$3.07-$3.57-$4.32 - -$3.03+14.01%Beat-1715.8%150 up, 0 downMay 2, 2024$167.00M
    Dec 31, 2023$0.55-$0.97-$2.64 - $3.13+156.70%Beat-84.8%174 up, 0 downFeb 22, 2024$2.81B
    Sep 30, 2023-$9.53-$2.05-$3.45 - -$0.62-364.88%Miss-476.7%14N/ANov 2, 2023$1.83B
    Jun 30, 2023-$3.62-$4.12-$4.62 - -$3.01+12.14%Beat-169.1%152 up, 0 downAug 3, 2023$344.00M
    Mar 31, 2023$0.19-$1.77-$3.61 - -$0.70+110.73%Beat-97.8%143 up, 1 downMay 4, 2023$1.86B
    Dec 31, 2022$3.61$4.60$3.75 - $5.56-21.52%Miss-68.0%142 up, 0 downFeb 23, 2023$5.08B
    Sep 30, 2022$2.53$3.11$1.77 - $5.39-18.65%Miss-67.1%131 up, 3 downNov 3, 2022$3.36B
    Jun 30, 2022$5.24$4.49$2.02 - $5.34+16.70%Beat-18.9%130 up, 1 downAug 3, 2022$4.75B
    Mar 31, 2022$8.58$5.62$1.89 - $7.72+52.67%Beat+202.1%122 up, 2 downMay 4, 2022$6.07B
    Dec 31, 2021$11.29$9.90$5.25 - $10.85+14.04%BeatN/A110 up, 0 downFeb 24, 2022$7.21B
    Sep 30, 2021$7.70$9.42$6.98 - $11.01-18.26%MissN/A11N/ANov 4, 2021$4.97B
    Jun 30, 2021$6.46$5.86$3.27 - $8.12+10.24%BeatN/A12N/AAug 5, 2021$4.35B
    Mar 31, 2021$2.84$2.47$0.82 - $5.56+14.98%BeatN/A12N/AMay 6, 2021$1.94B
    Dec 31, 2020-$0.69-$0.35-$0.82 - $0.17-97.14%MissN/A12N/AFeb 25, 2021$571.00M
    Sep 30, 2020-$0.59-$0.37-$0.95 - -$0.23-59.46%MissN/A12N/AOct 29, 2020$157.00M
    Jun 30, 2020-$0.31-$0.36-$0.53 - -$0.22+13.89%BeatN/A12N/AAug 5, 2020$67.00M
    Mar 31, 2020-$0.35-$0.36-$0.39 - -$0.28+2.78%BeatN/A10N/AMay 7, 2020$8.00M
    Dec 31, 2019-$0.37-$0.42-$0.45 - -$0.40+11.90%BeatN/A8N/AFeb 26, 2020$13.85M
    Sep 30, 2019-$0.37-$0.44-$0.46 - -$0.39+15.91%BeatN/A6N/ANov 6, 2019$17.05M
    Jun 30, 2019-$0.41-$0.45-$0.47 - -$0.40+8.89%BeatN/A5N/AAug 7, 2019$13.08M
    Mar 31, 2019-$0.40-$0.36-$0.45 - -$0.25-11.11%MissN/A7N/AMay 9, 2019$16.02M
    Dec 31, 2018-$1.78-$0.36-$0.45 - -$0.20-394.44%MissN/A7N/AMar 6, 2019$35.42M
    Sep 30, 2018-$0.52N/AN/AN/AN/AN/AN/AN/ADec 7, 2018$41.76M
    Jun 30, 2018-$0.29N/AN/AN/AN/AN/AN/AN/AJun 30, 2018$28.85M
    Last 34 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$7.27, after -$9.28 the year before. It was -$2.59 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$7.27N/A
    Dec 31, 2024-$9.28N/A
    Dec 31, 2023-$12.41-162.2%
    Dec 31, 2022$19.96-29.4%
    Dec 31, 2021$28.29N/A
    Dec 31, 2020-$1.94N/A
    Dec 31, 2019-$1.55N/A
    Dec 31, 2018-$2.59N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,43218
    2026Q2Jun 30, 20268,41117
    2026Q1Mar 31, 20266,87218
    2025Q4Dec 31, 20258,3857
    2025Q3Sep 30, 20256,96315
    2025Q2Jun 30, 20258,76513
    2025Q1Mar 31, 20257,66512
    2024Q4Dec 31, 20247,64718

    2026Q3 Earnings Call

    Opening remarks

    Lavina Talukdar Head of Investor Relations Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's third quarter 26 financial results and business update. You can access the press release issued this morning, as well as the slides that we will be reviewing, by going to the Investors section of our website. On today's call are Stéphane Bancel, our Chief Executive Officer; Stephen Hoge, our president; James Mock, our chief financial officer; and David Berman, our chief development officer. Before we begin, please note that this call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 2000. Please see slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. With that, I will turn the call over to Stéphane.

    Stéphane Bancel CEO Thank you, Lavina. Good morning or good afternoon, everyone. Thank you for joining us. We will start today with a review of the third quarter. James will then cover our financial results and outlook, followed by Stephen with our current business updates in infectious diseases. David will then review our clinical progress in oncology and rare diseases. I will come back quickly for a close on our key value drivers before Q&A. The Moderna team delivered a great third quarter, generating $1.4 billion in revenues, representing 29% growth year over year. Importantly, strong commercial performance translated into $200 million in net income for the quarter. We also ended the quarter with a strong balance sheet, with $8 billion in cash and investments, reflecting a combination of solid operational and commercial execution along with a highly successful convertible debt financing. And we continue to demonstrate financial discipline across the company, reducing cash cost by 10% compared to the third quarter of last year. Together, these strong results underscore our ability to deliver strong commercial performance while maintaining financial discipline and strengthening our financial position. During the quarter, we achieved several important milestones across our pipeline and our business. FDA approval of mFLUSIVA, making it Moderna's fifth approved product and the first mRNA-based influenza vaccine to reach the market. In Canada, we secured approvals of both mFLUSIVA and mCOMBRIAX yesterday, the local brand name for mCOMBRIAX, further expanding our respiratory portfolio internationally. In oncology, we are very proud to present positive Phase 3 data for intismeran autogene, our individualized cancer therapy being developed in partnership with Merck. The results demonstrated a significant clinical benefit, with a 42% reduction in the risk of recurrence or death in patients with resected melanoma.

    Frequently Asked Questions About MRNA

    When is Moderna's next earnings date?

    Moderna's next earnings report is expected for Feb 11, 2027.

    Did MRNA beat earnings estimates last quarter?

    Yes. Moderna reported EPS of $0.38 for the quarter ended Sep 30, 2026, above the -$1.10 estimate, a 134.55% surprise.

    What EPS do analysts expect from MRNA next quarter?

    The consensus EPS estimate for Moderna for the quarter ending Dec 31, 2026 is -$2.39 from 20 analysts, with estimates from -$4.20 to -$1.78.

    How often does MRNA beat earnings estimates?

    Moderna beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +26.55%.